Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Duek

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Life (Basel, Switzerland)|December 30, 2025
Immature Platelet Fraction as a Surrogate Marker of Thrombo-Inflammation in Hospitalized COVID-19 PatientsAdrian Duek, Alexandra Zimin, Yael Hershkop, et al.
Harefuah|March 14, 2023
[PROLONGED POST-COVID-19 ANEMIA]Yafit Segman, Adrian Duek, Yair Goldhechet, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 16, 2017
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literatureAdir Shaulov, Irit Avivi, Yael Cohen, et al.
Oral Diseases|May 24, 2018
Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosisMerav Leiba, Suha Jarjoura, Waseem Abboud, et al.
The Israel Medical Association Journal : IMAJ|October 30, 2022
Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kitAdrian Duek, Emmanuel Lellouche, Sharon Ben Baruch, et al.
Blood|January 18, 2015
Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPNJean Grisouard, Takafumi Shimizu, Adrian Duek, et al.
British Journal of Haematology|May 28, 2014
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysisMerav Leiba, Meirav Kedmi, Adrian Duek, et al.
Clinical and Experimental Nephrology|February 9, 2019
Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysisOlga Kukuy, Batia Kaplan, Sizilia Golderman, et al.
American Journal of Cancer Research|December 15, 2025
STK405759 targets microtubules, modulates STAT1, and enhances ruxolitinib efficacy in myeloproliferative neoplasmsGabriela Rozic, Yaara Makaros, Irit Shapira-Netanelov, et al.
Blood Cells, Molecules & Diseases|April 3, 2017
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patientsMerav Leiba, Sarah Malkiel, Ivan Budnik, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Life (Basel, Switzerland)|December 30, 2025
Immature Platelet Fraction as a Surrogate Marker of Thrombo-Inflammation in Hospitalized COVID-19 PatientsAdrian Duek, Alexandra Zimin, Yael Hershkop, et al.
Harefuah|March 14, 2023
[PROLONGED POST-COVID-19 ANEMIA]Yafit Segman, Adrian Duek, Yair Goldhechet, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 16, 2017
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literatureAdir Shaulov, Irit Avivi, Yael Cohen, et al.
Oral Diseases|May 24, 2018
Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosisMerav Leiba, Suha Jarjoura, Waseem Abboud, et al.
The Israel Medical Association Journal : IMAJ|October 30, 2022
Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kitAdrian Duek, Emmanuel Lellouche, Sharon Ben Baruch, et al.
Blood|January 18, 2015
Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPNJean Grisouard, Takafumi Shimizu, Adrian Duek, et al.
British Journal of Haematology|May 28, 2014
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysisMerav Leiba, Meirav Kedmi, Adrian Duek, et al.
Clinical and Experimental Nephrology|February 9, 2019
Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysisOlga Kukuy, Batia Kaplan, Sizilia Golderman, et al.
American Journal of Cancer Research|December 15, 2025
STK405759 targets microtubules, modulates STAT1, and enhances ruxolitinib efficacy in myeloproliferative neoplasmsGabriela Rozic, Yaara Makaros, Irit Shapira-Netanelov, et al.
Blood Cells, Molecules & Diseases|April 3, 2017
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patientsMerav Leiba, Sarah Malkiel, Ivan Budnik, et al.
Pageof 4